2025-06-03-Bernstein-联合健康集团（UNH）_我们对新任首席执行官的三大优先事项的看法以及股东会议的评论_16页_3mb

UnitedHealth Group Inc Summary

Core Content

UnitedHealth Group Inc (UNH) is undergoing a strategic and operational turnaround under the leadership of new CEO Steve Hemsley. The company's annual shareholder meeting highlighted key areas of focus, including restoring pricing discipline, restructuring the management team, and evaluating major strategic decisions. The report outlines the company's current financial status, future expectations, and the implications of these changes on its performance.

Main Points

Top Three Priorities for the New CEO

1. Resetting the Underwriting and Operational Culture

   • The immediate focus is on restoring pricing discipline, particularly in forecasting care and financial activity, including MA bids and commercial pricing.
   • A reset year for pricing discipline is expected in 2026, emphasizing no growth at the expense of margin and retaining only profitable business.
   • Intense central oversight of management processes and 2026 planning is anticipated to ensure operational rigor and a disciplined approach.

2. Establishing a Long-Term Management Team

   • The CEO aims to identify a successor and build a long-term leadership team.
   • A focus on internal talent is expected, with the company moving towards an operating turnaround and involving regional leaders and key business units in the process.
   • External talent may also be added, but primarily in "bench and depth" roles to evaluate and integrate over time.

3. Strategic Decisions

   • The company may consider splitting UHC and Optum Health to enhance growth potential and address anti-competitive concerns.
   • The decision to split would be evaluated based on the potential for Optum Health to operate independently and capitalize on the shift towards value-based care (VBC).

Shareholder Meeting Highlights

• Pricing Discipline: CEO Hemsley acknowledged the need for a renewed focus on pricing, citing previous misjudgments in care activity and cost trends.
• Optum Health Development: The CEO emphasized the importance of Optum Health in the transition to VBC and highlighted its formative stage in this process.
• Transparency Initiatives: New initiatives are being introduced to review company policies, practices, and performance measures related to risk assessment coding, managed care, and pharmacy services.
• Leadership Realignment: The management team and processes are being realigned to ensure appropriate leadership for both UHC and Optum.

Financial Outlook

• Price Target: The current price target for UNH is $377.00 USD, with an upside of 24% from the close price of $304.72 on June 2, 2025.
• Earnings Guidance: UNH will release its 2Q 2025 earnings report on July 29, providing a prudent 2025 outlook and initial 2026 guidance.
• Financial Metrics:
  • Revenues: Expected to grow from $400,278 million in FY24 to $467,714 million in FY26.
  • EBITDA: Projected to increase from $36,386 million in FY24 to $39,639 million in FY26.
  • EPS: Adjusted EPS is expected to rise from $27.66 in FY24 to $28.80 in FY26.
• Margins:
  • UHC Operating Margin: Expected to improve from 8.1% in FY24 to 8.8% in FY28.
  • Optum Health Margins: Projected to increase from 5-6% in FY24 to 7.5% in FY28, driven by improved underwriting and operational rigor.

Sector Trends and Challenges

• MA Margins: Expected to recover from 1% in 2025 to 4% by 2028, driven by reduced competition and increased pricing discipline.
• Medicaid Margins: Anticipated to recover over 2H25 to 2027, supported by state rate increases and stable enrollment post-Reconciliation bill.
• Risk Patient Growth: Optum Health is expected to see a slowdown in risk patient growth, from 650k-1m patients per year to 150k in 2026, and a return to 550k in 2028.

Key Information

• Market Cap: $276,424 million (as of FY24).
• EV (Enterprise Value): $333,535 million (as of FY24).
• Dividend Yield: 2.8%.
• Performance: UNH has experienced a decline in performance, with a YTD return of -39.8% and a 12M return of -38.7%.
• Relative Performance to SPX: -40.7% YTD and -51.2% 12M.
• Valuation Metrics: Adjusted P/E is expected to rise from 11.0 in FY24 to 13.4 in FY25 and fall to 10.6 in FY26.

Investment Implications

• The company maintains an Outperform rating with a price target of $377.00 USD.
• The focus on pricing discipline and transparency is expected to drive improved performance and long-term value.
• The potential split of UHC and Optum Health could lead to better valuation and growth opportunities, especially in government managed care.

Conclusion

UnitedHealth Group Inc is addressing its recent challenges through a focused approach on pricing discipline, leadership restructuring, and strategic evaluation. The company is expected to see improved financial performance and margin recovery over the next few years, with a clear path to long-term growth and value creation.